1 / 54

The Pharmacology & Toxicology of Local Anesthetics

The Pharmacology & Toxicology of Local Anesthetics. Terry C. Wicks, CRNA, MHS Catawba Valley Medical Center Hickory, NC. 1st: Our Focal Point, Nerve Fiber Types & Differential Blockade. Mechanism of Action (Na + ). Excitable membranes maintain an ( ATPase ) electro-chemical gradient.

jasia
Download Presentation

The Pharmacology & Toxicology of Local Anesthetics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Pharmacology & Toxicology of Local Anesthetics Terry C. Wicks, CRNA, MHS Catawba Valley Medical Center Hickory, NC

  2. 1st: Our Focal Point, Nerve Fiber Types & Differential Blockade...

  3. Mechanism of Action (Na+) • Excitable membranes maintain an (ATPase) electro-chemical gradient. • Sodium channels open briefly when the membrane is stimulated. • Sodium ions flow down the concentration gradient resulting in depolarization. CNS Cardiac Skeletal DRG DRG SNS Peripheral

  4. Mechanism of Action (Na+) • Exert their effects by binding to receptors in or near the voltage gated sodium channel. • Interrupt conduction in excitable tissues including axons, dendrites and muscle. • Dull sensation distal to the site of blockade.

  5. Mechanism of Action (Na+) • Sodium channels exist in three states: • Open (conducting) high affinity • Closed-resting (non-conducting) low affinity • Closed-inactive (non-conducting) high affinity • Tonic blockade (closed resting) • Phasic blockade (open & closed inactive)

  6. Model of Local Anesthetic Binding

  7. Mechanism of Action (K+) • Local anesthetics will engage potassium channels. • Blockade may be more stereo-selective for K+ than for Na+channels • Delayed repolarization may increase the refractory period, and action potential duration.

  8. Minimum Blocking Concentration

  9. Minimum Blocking Concentration • In vitro: independent of fiber diameter • In vivo: other factors influence clinical drug performance • Nerve length and myelination • Rate of traffic (use dependence) • Important for anti-arrhythmic effects or • Use at low concentrations • LA concentration & volume • Rate of diffusion of the drug

  10. Minimum Blocking Concentration • The concentration that just halts impulse propagation • 3 nodes of Ranvier for myelinated fibers or 5-6 mm for unmylinated fibers • Critical blocking length [CBL] • As the concentration of LA increases the critical blocking length decreases.

  11. Other Receptors I • G protein coupled receptors • Anti-inflammatory effects: Inhibition of human polymorphonuclear neutrophil priming without interfering with normal immune response. • Relative potency: chloroprocaine>tetracaine> procaine>lidocaine> mepivacaine>bupivacaine. • Anti-thrombotic effects: Inhibit platelet activating factor without interfering with normal coagulation. • Ca++/Mg++ATPase

  12. Other Receptors II • NMDA (N-methyl-D-aspartic acid) glutamate receptor. • AMPA (a-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid) receptor.

  13. Physicochemical Properties

  14. Dissociative Properties • Exist as weak bases, uncharged & able to penetrate tissue membranes (lipophilic). • In solution separate into charged cations and Cl- (hydrophilic). • As pH decreases ionization increases.

  15. pKa =Ph of 50% Dissociation

  16. Lipid Solubility Correlates with: • Potency • Duration of action • Protein binding • Toxicity

  17. Prototypical Local Anesthetics Ester Linked Amide Linked Lipophilic Linkage Hydrophilic Lipophilic Linkage Hydrophilic

  18. Molecular Pharmacology • Tertiary amines derived from ammonia as weak bases • Three part structural • lipophilic “head” • carbon chain • hydrophilic “tail”

  19. Molecular Pharmacology Ester Linked Agents Amide Linked Agents • Hydrolyzed by plasma esterases • chloroprocaine • procaine • tetracaine • benzocaine • cocaine • Bio-transformed by hepatic enzymes • lidocaine, prilocaine, etidocaine • mepivacaine, levo-bupivacaine, bupivacaine, ropivacaine

  20. Molecular Pharmacology • Lengthening the para-amino aromatic chain prolongs action and increases potency. • Adding a piperidine ring to the tail makes the compound resistant to hydrolysis. • Adding substituents to the aminoacyl carbon creates chiral molecules (asymmetrically substituted carbon) • mepivacaine • ropivacaine • bupivacaine

  21. Molecular Pharmacology • Sterioisomers have similar physico-chemical, but often have different pharmacodynamic properties • Racemic solutions have equal concentrations of S (sinister) and R (rectus) • Typically the S isomer is less toxic.

  22. Molecular Pharmacology: Chiral Molecules As described by Walter White, Episode 2, Season 1, “Breaking Bad”

  23. The Pharmacology of Local Anesthetics… Selected Agents

  24. Procaine “novacaine” • Prototype amino-ester local anesthetic • Metabolized by hydrolysis in the serum • Slow onset, duration of about one hour • Currently used as a substitute for lidocaine for SAB of short duration • Caudaequina syndrome has been reported after procaine spinal anesthesia (10% sol)

  25. Chloroprocaine • Hydrolyzed 4 times faster than procaine • Fetal & maternal metabolism is rapid • Sodium bisulfite: myo & neuro toxicity • EDTA: calcium binding & back pain • High diffusability, rapid onset, short duration • Dose: up to 600 mg

  26. Tetracaine • High lipid solubility and potency (toxicity) • Metabolized 1/3-1/4 the rate of chloroprocaine • 76% protein bound • Epinephrine prolongs duration by >50% • Dose: topical 100 mg, SAB 10-15 mg

  27. Aminoacyl Amides Lidocaine Family Mepivacaine Family • Straight chain hydrophilic amino tail • Hydrolysed by hepatic cytochrome P450 enzymes • Includes: • lidocaine • prilocaine • etidocaine • Piperidinering based hydophilicamino tail • Dealkylatedin the liver and renally excreted • Includes • mepivacaine • bupivacaine & (levo) • ropivacaine

  28. Lidocaine • The “standard” local anesthetic • Has anticonvulsant and antiarrhythmic properties • Epinephrine increases duration by 50% • Dose: 5 mg/kg plain, 7 mg/kg with epi • For local, IV regional, SAB, epidural, and peripheral nerve block

  29. Mepivacaine... • Toxicity similar to lidocaine • Rapid onset, duration slightly longer than lidocaine • Solution is a racemic mixture of R & S • Dose: 5 mg/kg plain, 7 mg/kg with epi • Clinical application similar to lidocaine

  30. Ropivacaine... • Formulated as the S enantiomer. • Potency, onset, duration, and dosage, similar to bupivacaine with less motor blockade toxicity and arrhythmogenicity.

  31. Bupivacaine • More lipid soluble (28 x), potent (4 x) and toxic than mepivacaine • Duration 4-6 hrs (95% protein bound) • Solution is a racemic mixture of R & S • No prolongation of effects by epi • Wide spread application • Max dose: 2.5 mg/kg

  32. Local Anesthetic Toxicity & Adverse Effects Manifestations & Management

  33. Allergic Reactions • Reaction typically follows prior sensitization • Can be either systemic or localized • Diagnosis based on history and symptoms • Cross sensitivity is unlikely

  34. Methemoglobinemia • Methemoglobinemiais the result of oxidation of hemoglobin • Central cyanosis will be evident when methemoglobin levels exceed 15% • Treated by administration of methylene blue1-2 mg/kg over 5 minutes

  35. Myotoxicity • High concentrations of LAs inhibit myocyte energy production at the mitochondrial level • Effects myocardial and skeletal muscle • Effects are proportional to lipid solubility

  36. Neurotoxicity • Elevation of intracellular Ca++ • Membrane disruption and permanent depolarization • Activation of caspaseenzymes

  37. Transient Neurologic Symptoms • Pain and dysesthesia in buttocks and lower extremities after resolution of spinal anesthesia • Sx occur without sensory or motor deficits, normal MRI and EP studies • Most common after lidocaine spinals, but can occur with other local anesthetics • Course is self limiting, & treatment is symptomatic

  38. CaudaEquina Syndrome • Permanent bladder and bowel dysfunction, loss of sensory and motor function in LE • First report after continuous SAB, but there are reports after single shot SABs • Most commonly lidocaine is the offending agent, but does occur with other agents

  39. Systemic Toxicity • Severity is proportional to the rate of delivery to central circulation • Dose • Tissue vascularity • Use of vasoconstrictors • Toxicity of drug • Rate of redistribution & metabolism

  40. Systemic Toxicity: CNS • Vertigo, tinnitus, dysphoria • Restlessness, numbness of tongue, circumoral tissues • Slurred speech, muscle twitching • Tonic clonicseizures • CNS depression, coma, & apnea • Metabolic & respiratory acidosis lower the seizure threshold

  41. Systemic Toxicity: CVS • Increased heart rate & blood pressure • Appearance of ectopy • Varying degrees of heart block • Hypotension, bradyarrhythmia, • Asystole • Vasoconstriction at low doses (local) vasodilation at high doses (systemic)

  42. Prevention of Toxicity • Use lowest effective dose • Inject incrementally • Aspirate prior to injection • Use of intravascular marker • Epinephrine • Fentanyl (laboring patients) • Lidocaine • Use of ultrasound? Then evidence is mounting. ASA Newsletter April 2012 Vol 76 No 4 22-25

  43. Treatment Of Toxicity • Effective airway management • 100% oxygen (hypoxia) • Effective ventilation (respiratory acidosis) • Stop seizures • Benzo’s • Propofol • ACLS • Lipid Rescue • Cardiopulmonary Bypass Regional Anesthesia & Pain Medicine Vol. 35 No. 2 March-April 2010

  44. Lipid Infusion: Cardiac Arrest • Intralipid 20% 1.5 ml/kg over 1 minute • Continue infusion at 0.25 ml/kg/min • Continue CPR • Repeat bolus every 3-5 minutes up to 3 ml kg • Increase rate to 0.5 ml/kg if BP declines • A maximum of 8 ml/kg is recommended • Now considered a first line component of therapy Newly created registry of lipid use is accessible at www.lipidregistry.org.

  45. Lipid Infusion: Why does it work? • Lipid emulsion may act as a “sink”. • May also act as a metabolic substrate for myocytes. • 90% of aerobic cardiac myocyte ATP is from fatty acid metabolism • May increase intramyocyte calcium concentrations • May reverse LA induced vasodilation. • Used to treat toxicity from other highly lipid soluble drugs

  46. Problems Studying Lipid Rescue • Intact rodent, canine, and isolated heart models show positive results. • Porcine models…not so much. Confounded by: • Hypoxemia and acidosis based models • High dose vasopressor treatment models • Maybe pigs don’t like lipid emulsion (compliment activated pseudo-allergy) • Intralipid® does not activate complement in humans

  47. Lipid Infusion • Anecdotal reports of effectiveness are becoming more common place. • Resolution of CV toxicity, arrhythmias, and CNS toxicity are generally prompt. • Paradoxically treatment with epinephrine, and vasopressin, restores perfusion more quickly than lipid alone, but survival may be reduced. Visit www.lipidrescue.org

  48. Local Anesthetic Toxicity:A Case Report • 31 y.o. male • Untreated HTN • Work related trauma to L hand • NPO X 9 hrs • Posted for debridement & tendon repair • Plan: Trans-arterial axillary block with 20 cc lidocaine 2% and 20 cc Chirocaine 0.75%, with 1:200k epinephrine. • Monitors, oxygen, and versed 2.0 pre-block.

  49. During Injection…uh oh…

  50. Management • Additional 2.5 mg versed, 150 mg propofol. • Positive pressure hyperventilation with 100% oxygen. • Oral airway. • Spill contents of crash cart on floor. • ABG: ph 7.01, PO2 111, PCO2 90, HCO3 23, BE –10. • 12 Lead EKG. • Chest X-ray. • Patient regained consciousness after one hour 15 minutes. iphone app: Lipid ALS

More Related